ストックスクリーナーアプリを入手
40.97
1.29%
0.52
アフターアワーズ：
40.97
前日終値:
$40.45
開ける：
$41.53
24時間の取引高:
321.34K
Relative Volume:
0.92
時価総額：
$1.85B
収益：
-
当期純損益:
$-75.27M
株価収益率:
-24.15
EPS:
-1.6963
ネットキャッシュフロー:
$-66.67M
1週間 パフォーマンス:
+3.49%
1か月 パフォーマンス:
+1.19%
6か月 パフォーマンス:
+16.79%
1年 パフォーマンス:
+220.33%
1日の値動き範囲:
$40.42
$43.73
1週間の範囲:
$36.50
$43.73
52週間の値動き範囲:
$11.77
$46.46
Sionna Therapeutics Inc Stock (SION) Company Profile
名前
Sionna Therapeutics Inc
セクター
電話
617-819-2020
住所
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
40.97 | 1.83B | 0 | -75.27M | -66.67M | -1.6963 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Citizens | Mkt Outperform |
| 2025-12-01 | ダウングレード | RBC Capital Mkts | Sector Perform → Underperform |
| 2025-11-19 | 開始されました | BTIG Research | Buy |
| 2025-09-03 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-03-04 | 開始されました | Guggenheim | Buy |
| 2025-03-04 | 開始されました | Stifel | Buy |
| 2025-03-04 | 開始されました | TD Cowen | Buy |
すべてを表示
Sionna Therapeutics Inc (SION) 最新ニュース
A Look At Sionna Therapeutics (SION) Valuation After Its Strong 1 Year Return And Premium P/B Ratio - Yahoo Finance
Wedbush initiates Sionna Therapeutics stock with Outperform rating By Investing.com - Investing.com South Africa
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch - AOL.com
Sionna Therapeutics, Inc. $SION Shares Acquired by Jennison Associates LLC - MarketBeat
Trial of SION-719 as Trikafta add-on therapy in CF is fully enrolled - Cystic Fibrosis News Today
JonesTrading Forecasts Strong Price Appreciation for Sionna Therapeutics (NASDAQ:SION) Stock - MarketBeat
Jones Trading raises Sionna Therapeutics price target on trial progress By Investing.com - Investing.com Canada
EDGAR Filing Documents for 0001628280-26-027501 - SEC.gov
Sionna Therapeutics (NASDAQ: SION) details 2026 virtual meeting, board elections - Stock Titan
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch - The Motley Fool
Sionna Therapeutics Completes Phase 2a Enrollment for SION-719 in Cystic Fibrosis - marketscreener.com
Sionna completes enrollment in cystic fibrosis drug trial By Investing.com - Investing.com Canada
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial for SION-719 in Cystic Fibrosis - Quiver Quantitative
First trial of Sionna's CF add-on drug reaches full enrollment - Stock Titan
Sionna Therapeutics (SION) Q1 2025 earnings summary - Quartr
Sionna Therapeutics (SION) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
Sionna Therapeutics (SION) Cantor Global Healthcare Conference 2025 Summary - Quartr
Sionna Therapeutics (SION) Leerink Global Healthcare Conference 2026 Summary - Quartr
Sionna Therapeutics (SION) Q4 2025 earnings summary - Quartr
Sionna Therapeutics (SION) Q2 2025 earnings summary - Quartr
Sionna Therapeutics (SION) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 11.3%What's Next? - MarketBeat
Sionna Therapeutics Insider Sold Shares Worth $2,472,343, According to a Recent SEC Filing - marketscreener.com
OrbiMed Advisors sells $2.47m in Sionna Therapeutics stock By Investing.com - Investing.com Australia
Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 52,397 Shares - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Director Sells $2,341,097.96 in Stock - MarketBeat
Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 2,948 Shares of Stock - MarketBeat
Sionna Therapeutics director Peter A. Thompson sells $2.47m in stock - Investing.com
OrbiMed Advisors sells $2.47m in Sionna Therapeutics stock - Investing.com
Sionna Therapeutics director Peter A. Thompson sells $2.47m in stock By Investing.com - Investing.com India
OrbiMed fund tied to Sionna (NASDAQ: SION) director trims 55K shares - Stock Titan
OrbiMed-backed Sionna (NASDAQ: SION) sees fund share sale - Stock Titan
Why Sionna Therapeutics Stock Is Sinking Now - TipRanks
OrbiMed (SION) cuts Sionna stake to 6.6% after April share sales - Stock Titan
Is Sionna Therapeutics (SION) stock expensive relative to growth (-3.76%) 2026-04-18Weak Sell Rating - Cổng thông tin điện tử tỉnh Tây Ninh
OrbiMed Advisors sells Sionna Therapeutics (SION) stock worth $22.9m By Investing.com - Investing.com UK
Peter Thompson Sells 235,863 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - MarketBeat
Orbimed Advisors Llc Sells 235,863 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 47,814 Shares - MarketBeat
Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 226,906 Shares of Stock - MarketBeat
Sionna Therapeutics (SION) director Thompson sells $22.9 million in stock By Investing.com - Investing.com Canada
Sionna Therapeutics (SION) director Thompson sells $22.9 million in stock - Investing.com
Sionna Therapeutics(SION.US) Director Sells US$22.95 Million in Common Stock - Moomoo
OrbiMed Advisors sells Sionna Therapeutics (SION) stock worth $22.9m - Investing.com
OrbiMed fund linked to Sionna Therapeutics (SION) director sells 510K shares - Stock Titan
OrbiMed entities sell Sionna Therapeutics (SION) stock under 10b5-1 plan - Stock Titan
Operating cash flow per share of Sionna Therapeutics, Inc. – NASDAQ:SION - TradingView
Sionna Therapeutics stock hits all-time high at 45.17 USD By Investing.com - Investing.com Australia
Why Sionna Therapeutics Stock Is Sliding After a Surge - TipRanks
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Sionna Therapeutics Inc (SION) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):